MLTX MoonLake Immunotherapeutics

  1. Stocks
  2. Healthcare
  3. NASDAQ: MLTX

Price (delayed)

$12.9

Market cap

$1.1B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.84

Enterprise value

$721.5M

?
Relative Growth: Rel. Growth: 3
Relative Strength: Rel. Strength: 8
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 2
Highlights
MLTX's equity has soared by 69% QoQ and by 21% YoY
MLTX's quick ratio has surged by 52% since the previous quarter but it is down by 23% year-on-year
The net income has declined by 48% year-on-year and by 2.2% since the previous quarter
MoonLake Immunotherapeutics's EPS has decreased by 38% YoY
Sector: Healthcare
Industry: Biotechnology
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of MLTX

MLTX stock price

How has the MoonLake Immunotherapeutics stock price performed over time
Intraday
-3.59%
1 week
3.53%
1 month
-18.15%
1 year
-75.45%
YTD
-2.12%
QTD
-33.74%

Financial performance

How have MoonLake Immunotherapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$268.34M
Net income
-$265.22M
Gross margin
N/A
Net margin
N/A
The net income has declined by 48% year-on-year and by 2.2% since the previous quarter
The operating income is down by 34% year-on-year

Price vs fundamentals

How does MLTX's price correlate with its fundamentals

Growth

What is MoonLake Immunotherapeutics's growth rate over time

Valuation

What is MoonLake Immunotherapeutics stock price valuation
P/E
N/A
P/B
2.22
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
MoonLake Immunotherapeutics's EPS has decreased by 38% YoY
MLTX's equity has soared by 69% QoQ and by 21% YoY
The price to book (P/B) is 68% lower than the 5-year quarterly average of 7.3 and 28% lower than the last 4 quarters average of 3.2

Efficiency

How efficient is MoonLake Immunotherapeutics business performance
The ROIC has plunged by 148% YoY and by 12% from the previous quarter
The company's return on equity has shrunk by 97% YoY but it rose by 3.7% QoQ
The company's return on assets has shrunk by 61% YoY but it rose by 4.3% QoQ

Dividends

What is MLTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MLTX.

Financial health

How did MoonLake Immunotherapeutics financials performed over time
MLTX's quick ratio has surged by 52% since the previous quarter but it is down by 23% year-on-year
The current ratio is up by 46% since the previous quarter but it is down by 25% year-on-year
The debt is 76% smaller than the equity
MLTX's equity has soared by 69% QoQ and by 21% YoY
MoonLake Immunotherapeutics's debt to equity has decreased by 40% QoQ but it has increased by 14% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.